PTGX Earnings Date: Nov 5, 2026 (Estimated) — Protagonist Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PTGX's next earnings date?
Protagonist Therapeutics, Inc. (PTGX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.50 on revenue of $238.5M.
How did PTGX do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Protagonist Therapeutics, Inc. posted EPS of $2.29 versus the $2.23 estimate, a beat of 24.5%. Revenue was $213.5M against a $198.7M estimate. The stock's 1-day post-earnings move was +6.5%.
How much does PTGX stock move after earnings?
PTGX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.8% (up or down) in the day after earnings.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 2.23 | 2.29 | +24.46% | $213.5M | ✅ Beat | +6.45% | +10.70% | +8.36% |
| 2026-05-05 | Q1 2026 | -0.65 | 0.05 | +107.69% | $56.4M | ✅ Beat | +4.80% | +0.75% | +3.61% |
| 2026-02-25 | Q4 2025 | -0.54 | -0.69 | -27.78% | $7.4M | ❌ Miss | -0.33% | +4.47% | +19.36% |
| 2025-11-06 | Q3 2025 | -0.62 | -0.62 | +0.00% | $4.7M | ➖ Inline | -0.30% | +4.34% | +13.12% |
| 2025-08-06 | Q2 2025 | -0.53 | -0.55 | -3.77% | $5.5M | ❌ Miss | -5.39% | +5.30% | +12.37% |
| 2025-02-21 | Q4 2024 | 1.03 | 1.98 | +92.23% | $170.6M | ✅ Beat | +0.68% | -5.59% | +36.79% |
| 2024-11-07 | Q3 2024 | -0.63 | -0.54 | +14.29% | $4.7M | ✅ Beat | -2.90% | -13.80% | -14.93% |
| 2024-08-06 | Q2 2024 | -0.60 | -0.50 | +16.67% | $4.2M | ✅ Beat | +1.17% | +13.44% | +16.79% |
Showing last 8 quarters.